N-(6-oxoheptyl)butanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-(6-oxoheptyl)butanamide
• 化学式: C₁₁H₂₁NO₂
• 分子量: 199.29
• InChiKey: YRHFMJRHXYBFKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Polypeptide protracting tags
  申请人：Dorwald Florencio Zaragoza

  公开号：US20090111730A1

  公开（公告）日：2009-04-30

  Method for increasing (protracting) half-life of LGP analogs in plasma and novel derivatives of such peptides based on covalently linking them to a tetrazole moiety which acts as a carboxylic acid bioisostere.

  一种增加LGP类似物在血浆中半衰期的方法以及基于共价连接到四唑基团的新型衍生物，该四唑基团作为羧酸生物异构体。
• CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES
  申请人：Genentech, Inc.

  公开号：EP3088004A1

  公开（公告）日：2016-11-02

  Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.

  用非交联的高活性半胱氨酸氨基酸取代母体抗体的一个或多个氨基酸，就能设计出抗体。抗体片段也可以用一个或多个半胱氨酸氨基酸进行工程化，形成半胱氨酸工程化抗体片段（ThioFab）。本文提供了设计、制备、筛选和选择半胱氨酸工程抗体的方法。半胱氨酸工程抗体（Ab），可选择带有白蛋白结合肽（ABP）序列，通过连接体（L）与一种或多种药物分子（D）共轭，形成具有式 I 的半胱氨酸工程抗体-药物共轭物：Ab-(L-D)p I 其中 p 为 1 至 4。本研究公开了半胱氨酸工程抗体药物化合物和组合物的诊断和治疗用途。
• Combination Therapy With Antibody-Drug Conjugates
  申请人：Oflazoglu Ezogelin

  公开号：US20130022627A1

  公开（公告）日：2013-01-24

  Methods for the treatment of Hodgkin's lymphoma comprising administering both a chemotherapeutic regimen and an antibody-drug conjugate compound to a subject in need thereof are provided.
• US20140256785A1
  申请人：——

  公开号：US20140256785A1

  公开（公告）日：2014-09-11
• ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
  申请人：AGENSYS, INC.

  公开号：US20150306245A1

  公开（公告）日：2015-10-29

  Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.